JPWO2020180121A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020180121A5
JPWO2020180121A5 JP2020541718A JP2020541718A JPWO2020180121A5 JP WO2020180121 A5 JPWO2020180121 A5 JP WO2020180121A5 JP 2020541718 A JP2020541718 A JP 2020541718A JP 2020541718 A JP2020541718 A JP 2020541718A JP WO2020180121 A5 JPWO2020180121 A5 JP WO2020180121A5
Authority
JP
Japan
Prior art keywords
antibody conjugate
cancer
alkyl
independently
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020541718A
Other languages
English (en)
Japanese (ja)
Other versions
JP7664045B2 (ja
JP2022522547A5 (https=
JP2022522547A (ja
Publication date
Priority claimed from KR1020200027373A external-priority patent/KR102503143B1/ko
Application filed filed Critical
Priority claimed from PCT/KR2020/003100 external-priority patent/WO2020180121A1/ko
Publication of JP2022522547A publication Critical patent/JP2022522547A/ja
Publication of JPWO2020180121A5 publication Critical patent/JPWO2020180121A5/ja
Publication of JP2022522547A5 publication Critical patent/JP2022522547A5/ja
Priority to JP2025009671A priority Critical patent/JP2025076435A/ja
Application granted granted Critical
Publication of JP7664045B2 publication Critical patent/JP7664045B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020541718A 2019-03-06 2020-03-05 ヒトdlk1に対する抗体を含む抗体薬物コンジュゲート及びその使用 Active JP7664045B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025009671A JP2025076435A (ja) 2019-03-06 2025-01-23 ヒトdlk1に対する抗体を含む抗体薬物コンジュゲート及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20190025987 2019-03-06
KR10-2019-0025987 2019-03-06
KR1020200027373A KR102503143B1 (ko) 2019-03-06 2020-03-04 인간 dlk1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
KR10-2020-0027373 2020-03-04
PCT/KR2020/003100 WO2020180121A1 (ko) 2019-03-06 2020-03-05 인간 dlk1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025009671A Division JP2025076435A (ja) 2019-03-06 2025-01-23 ヒトdlk1に対する抗体を含む抗体薬物コンジュゲート及びその使用

Publications (4)

Publication Number Publication Date
JP2022522547A JP2022522547A (ja) 2022-04-20
JPWO2020180121A5 true JPWO2020180121A5 (https=) 2023-03-13
JP2022522547A5 JP2022522547A5 (https=) 2023-03-13
JP7664045B2 JP7664045B2 (ja) 2025-04-17

Family

ID=72337989

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020541718A Active JP7664045B2 (ja) 2019-03-06 2020-03-05 ヒトdlk1に対する抗体を含む抗体薬物コンジュゲート及びその使用
JP2025009671A Pending JP2025076435A (ja) 2019-03-06 2025-01-23 ヒトdlk1に対する抗体を含む抗体薬物コンジュゲート及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025009671A Pending JP2025076435A (ja) 2019-03-06 2025-01-23 ヒトdlk1に対する抗体を含む抗体薬物コンジュゲート及びその使用

Country Status (6)

Country Link
US (1) US20220339291A1 (https=)
EP (1) EP3936150A4 (https=)
JP (2) JP7664045B2 (https=)
BR (1) BR112021017303A2 (https=)
MX (1) MX2021010453A (https=)
WO (1) WO2020180121A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101628872B1 (ko) * 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
AU2016359234B2 (en) 2015-11-25 2022-09-08 Ligachem Biosciences Inc. Conjugates comprising peptide groups and methods related thereto
HRP20240795T1 (hr) 2015-11-25 2024-09-13 Ligachem Biosciences Inc. Konjugati koji se sastoje od samozapaljujućih skupina i postupci povezani s njima
KR102847350B1 (ko) 2015-11-25 2025-08-19 주식회사 리가켐바이오사이언스 분지된 링커를 포함하는 항체-약물 접합체 및 이의 제조방법
MX2019011655A (es) 2017-03-29 2019-12-19 Legochem Biosciences Inc Profarmaco de dimero de pirrolobenzodiazepina y compuesto conjugado ligando-conector de este.
JP7459063B2 (ja) 2018-05-09 2024-04-01 レゴケム バイオサイエンシズ, インク. 抗-cd19抗体薬物複合体に関連する組成物および方法
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
KR20250009592A (ko) 2022-04-12 2025-01-17 미네르바 바이오테크놀로지 코포레이션 항-가변 muc1* 항체 및 그의 용도

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
DE3852304T3 (de) 1987-03-02 1999-07-01 Enzon Labs Inc., Piscataway, N.J. Organismus als Träger für "Single Chain Antibody Domain (SCAD)".
EP0305481B1 (en) 1987-03-20 1993-09-29 Creative Biomolecules, Inc. Leader sequences for the production of recombinant proteins
EP0305500B1 (en) 1987-03-20 1994-11-09 Creative Biomolecules, Inc. Process for the purification of recombinant polypeptides
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
CN103073641B (zh) * 2006-11-10 2015-01-21 株式会社立富泰克 在体内具有抗肿瘤活性的抗人Dlk-1抗体
ES2527521T3 (es) * 2008-03-17 2015-01-26 Livtech Inc. Anticuerpos antihumanos frente a Dlk-1 que tienen actividad antitumoral
KR101438265B1 (ko) * 2011-04-04 2014-09-05 한국생명공학연구원 Dlk1 특이적 인간 항체 및 이를 포함하는 약학적 조성물
WO2012138102A2 (ko) * 2011-04-04 2012-10-11 한국생명공학연구원 Dlk1 특이적 인간 항체 및 이를 포함하는 약학적 조성물
HUE045348T2 (hu) 2011-05-08 2019-12-30 Legochem Biosciences Inc Fehérje-hatóanyag konjugátumok és eljárás elõállításukra
KR101628872B1 (ko) 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
KR102847350B1 (ko) 2015-11-25 2025-08-19 주식회사 리가켐바이오사이언스 분지된 링커를 포함하는 항체-약물 접합체 및 이의 제조방법
GB201617466D0 (en) * 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
SI3579883T1 (sl) * 2017-02-08 2021-12-31 Adc Therapeutics Sa Konjugati pirolobenzodiazepin-protitelo
KR101966672B1 (ko) 2017-03-22 2019-04-09 신화인터텍 주식회사 파장 변환 부재 및 이를 포함하는 디스플레이 장치
MX2019011655A (es) 2017-03-29 2019-12-19 Legochem Biosciences Inc Profarmaco de dimero de pirrolobenzodiazepina y compuesto conjugado ligando-conector de este.
WO2018182341A1 (ko) 2017-03-29 2018-10-04 주식회사 레고켐 바이오사이언스 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물
KR102286050B1 (ko) 2017-06-23 2021-08-03 현대자동차주식회사 차량 네트워크에서 진단 오류 방지를 위한 방법 및 장치
KR20190018400A (ko) * 2017-08-14 2019-02-22 주식회사 레고켐 바이오사이언스 EGFRvIII에 대한 항체를 포함하는 항체 약물 접합체
KR102125032B1 (ko) * 2017-09-08 2020-06-19 주식회사 와이바이오로직스 인간 dlk1에 대한 항체 및 이의 용도
KR20200084802A (ko) * 2019-01-03 2020-07-13 주식회사 레고켐 바이오사이언스 안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도

Similar Documents

Publication Publication Date Title
JP2021063058A5 (https=)
JP2021523232A5 (https=)
EP4321180A1 (en) Antibody-drug conjugate including antibody against human cldn18.2, and use thereof
JP2019503980A5 (https=)
JP2019503979A5 (https=)
CA2835576C (en) Protein-active agent conjugates and method for preparing the same
JP2019503981A5 (https=)
HRP20240795T1 (hr) Konjugati koji se sastoje od samozapaljujućih skupina i postupci povezani s njima
JP7664045B2 (ja) ヒトdlk1に対する抗体を含む抗体薬物コンジュゲート及びその使用
AU2020233532B2 (en) Antibody-drug conjugates including antibody against human DLK1, and use thereof
JPWO2019215510A5 (https=)
JPWO2020180121A5 (https=)
JP2024160336A (ja) トリス構造を有するリンカーを含むリガンド―薬物複合体
WO2024189428A1 (en) Antibody-drug conjugate comprising antibodies against human l1cam and uses thereof
JPWO2022211508A5 (https=)
JPWO2021260438A5 (https=)
RU2021128538A (ru) Коньюгаты антитело-лекарственное средство, включающие антитело против человеческого dlk1, и их применение
RU2024133074A (ru) Конъюгат антитело-лекарственное средство, содержащий антитело к trop2 человека, и его применение
JP2025511705A (ja) ヒトtrop2に対する抗体を含む抗体-薬物コンジュゲート及びその使用
KR102501394B1 (ko) 트리스 구조를 가지는 링커를 포함하는 리간드-약물 접합체
RU2025127084A (ru) Конъюгат антитело-лекарственное средство, содержащий антитела против l1cam человека, и его применение
RU2020140202A (ru) Композиции и способы, относящиеся к конъюгатам лекарственных средств с антителами против cd19
JPWO2023194800A5 (https=)
TW202344271A (zh) 包含針對人cldn18.2的抗體的抗體藥物偶聯物及其用途
NZ778812B2 (en) Antibody-drug conjugates including antibody against human dlk1, and use thereof